HOME >> MEDICINE >> NEWS
Drug aimed at Huntington's eases chorea, the disease's hallmark feature

A drug widely available in Europe and Canada but not the United States dramatically eases one of the most disabling symptoms of Huntingtons disease, involuntary writhing movements known as chorea, according to a study in the Feb. 14 issue of the journal Neurology.

The medication, tetrabenazine, is currently being reviewed by the U.S. Food and Drug Administration. If approved, the medication would be the first authorized by the agency expressly for the treatment of Huntingtons disease, which affects about 30,000 people in the United States.

In a randomized, controlled study conducted in 84 patients at 16 sites around the nation, doctors found that the medication cut down involuntary movement on average by about 25 percent, with many patients experiencing a greater improvement. Overall, patients who received the medication were six times as likely to be considered by their doctors to have improved considerably, compared to participants who received a placebo.

Neuroleptic drugs like haloperidol (Haldol) are currently in widespread use in the United States to suppress chorea, but the effect of these drugs on chorea has never been studied in a systematic way, and they have a number of troublesome side effects, such as blunting of personality, loss of voluntary movement, and hindering balance. Our study showed that tetrabenazine, when appropriately dosed, can decrease chorea without causing those side effects, said Frederick J. Marshall, M.D., a neurologist at the University of Rochester Medical Center who led the study conducted by the Huntington Study Group. The study was funded by Prestwick Pharmaceuticals of Washington, D.C., the company that owns the rights to develop and sell the medication in the United States.

Tetrabenazine was originally developed in the 1950s to treat psychosis, but was quickly pushed aside by more effective medications. But doctors in the United Kingdom found it to be effective to treat the excessive involuntar
'"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
13-Feb-2006


Page: 1 2 3 4

Related medicine news :

1. Science of healthy foods subject of grant aimed at university students
2. Drug ads aimed at cancer patients difficult to read, make more appeals to effectiveness than safety
3. Cardiovascular flow disturbances study aimed at improving diagnosis and treatment
4. Endocrinologist-directed intervention aimed at primary care physicians improves diabetes care
5. New technology to speed up research into Huntingtons disease
6. Study identifies possible mechanism for brain damage in Huntingtons disease
7. Study identifies potential drug target for Huntingtons disease
8. Neural transplants provide persistent benefit in patients with Huntingtons disease
9. Rush designated Center of Excellence by Huntingtons Disease Society of America
10. A broader look at cardiac CTA images often finds diseases/disorders beyond the heart
11. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drug aimed Huntington eases chorea the disease hallmark feature

(Date:9/1/2015)... Toronto, ON (PRWEB) , ... September 01, 2015 ... ... Trade Secrets, a leading retailer of professional hair salons. This highly anticipated partnership ... all of the Curl Keeper™ Styling Collection. Founder Jonathan Torch and the Curly ...
(Date:8/31/2015)... ... , ... The PT Outcomes Registry is an organized system for collecting data ... Registry is being developed by the American Physical Therapy Association (APTA). , Al Amato, ... to contribute FOTO Outcomes measures as one of the primary global outcomes measures to ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... industry, released their latest predictive use case focused on helping hospital perform under ... Under this program, hospital payments are adjusted based on performance across four domains ...
(Date:8/31/2015)... ... 2015 , ... Cosmetic Town Journal is an online plastic ... a successful cosmetic procedure; from publishing encyclopedic medical articles to inform patients and ... to help. , It is clear that the Cosmetic Town aesthetic surgery community ...
(Date:8/31/2015)... ... 2015 , ... Dental clinicians from Newcastle University, United Kingdom, ... learn more about its integrated approach to diabetes care. , Philip Preshaw, BDS, ... Medicine at Newcastle University, and Susan Bissett, National Institute for Health Research Clinical ...
Breaking Medicine News(10 mins):Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4
(Date:8/31/2015)... Regen BioPharma, Inc. (OTCBB: RGBP) and ... means of delivering its patented (US Patent 8,263,571) ... utilizing a clinically approved formulation as delivery system.  ... gene silencing therapeutics in which the gene silencing ... body.  By utilizing a local delivery system, potential ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , ... SNY ; EURONEXT: SAN) and the life sciences team ... improve care and outcomes for people with type 1 ... diabetes treatments and devices with Google,s expertise in analytics, ... will explore how to improve diabetes care by developing ...
(Date:8/31/2015)... 31, 2015  Qualcomm Incorporated (NASDAQ: QCOM ... Life, Inc., is collaborating with Davita Healthcare ... solutions powered by Qualcomm Life,s 2net™ Device Connectivity ... continuous care, informed interventions and better management of ... Life,s annual Connect 2015 ecosystem conference ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
Cached News: